Dysregulation of global microRNA expression in splenic marginal zone lymphoma and influence of chronic hepatitis C virus infection

Leukemia

Volumn 26, Issue 7, 2012, Pages 1654-1662

  Peveling Oberhag, J ^a,b   Crisman, G ^c   Schmidt, A ^d   Doring C ^b   Lucioni, M ^e   Arcaini, L ^e   Rattotti, S ^e   Hartmann, S ^b   Piiper, A ^a   Hofmann, W P ^a   Paulli, M ^e   Kuppers R ^d   Zeuzem, S ^a   Hansmann, M L ^b  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b GOETHE UNIVERSITY   (Germany)

^c UNIVERSITY OF L'AQUILA   (Italy)

^d UNIVERSITY OF DUISBURG ESSEN   (Germany)

^e UNIVERSITY OF PAVIA   (Italy)

Author keywords

HCV; lymphoma; microRNA; miR 26b; splenic marginal zone lymphoma; virus

Indexed keywords

MICRORNA; MICRORNA 125A; MICRORNA 126; MICRORNA 139; MICRORNA 146A; MICRORNA 155; MICRORNA 21; MICRORNA 26B; MICRORNA 345; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER SURGERY; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HEPATITIS C; HUMAN; HUMAN TISSUE; IN SITU HYBRIDIZATION; MALE; PRIORITY JOURNAL; QUANTITATIVE ASSAY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPLENECTOMY; SPLENIC MARGINAL ZONE LYMPHOMA;

ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; IN SITU HYBRIDIZATION; LYMPHOMA, B-CELL, MARGINAL ZONE; MALE; MICRORNAS; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SPLEEN; SPLENIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84863778143     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2012.29     Document Type: Article

References (59)

1. Swerdlow SH, Campo E, Harris NL, Pileri SA, Stein H, Thiele J et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. IARC Press: Lyon, 2008.
2. Dufresne SD, Felgar RE, Sargent RL, Surti U, Gollin SM, McPhail ED et al. Defining the borders of splenic marginal zone lymphoma: a multiparameter study. Hum Pathol 2010; 41: 540-551.
3. Dungarwalla M, Appiah-Cubi S, Kulkarni S, Saso R, Wotherspoon A, Osuji N et al. High-grade transformation in splenic marginal zone lymphoma with circulating villous lymphocytes: the site of transformation influences response to therapy and prognosis. Br J Haematol 2008; 143: 71-74.
4. He L, Hannon GJ. MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet 2004; 5: 522-531.
5. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer 2006; 6: 857-866.
6. Liu X, Wang T, Wakita T, Yang W. Systematic identification of microRNA and messenger RNA profiles in hepatitis C virus-infected human hepatoma cells. Virology 2010; 398: 57-67.
7. Varnholt H, Drebber U, Schulze F, Wedemeyer I, Schirmacher P, Dienes HP et al. MicroRNA gene expression profile of hepatitis C virus-associated hepatocellular carcinoma. Hepatology 2008; 47: 1223-1232.
8. Durand T, Di Liberto G, Colman H, Cammas A, Boni S, Marcellin P et al. Occult infection of peripheral B cells by hepatitis C variants which have low translational efficiency in cultured hepatocytes. Gut 2010; 59: 934-942.
9. Simonetti RG, Camma C, Fiorello F, Cottone M, Rapicetta M, Marino L et al. Hepatitis C virus infection as a risk factor for hepatocellular carcinoma in patients with cirrhosis. A case-control study. Ann Intern Med 1992; 116: 97-102.
10. Ferri C, Monti M, La Civita L, Longombardo G, Greco F, Pasero G et al. Infection of peripheral blood mononuclear cells by hepatitis C virus in mixed cryoglobulinemia. Blood 1993; 82: 3701-3704.
11. Mele A, Pulsoni A, Bianco E, Musto P, Szklo A, Sanpaolo MG et al. Hepatitis C virus and B-cell non-Hodgkin lymphomas: an Italian multicenter case-control study. Blood 2003; 102: 996-999.
12. Silvestri F, Pipan C, Barillari G, Zaja F, Fanin R, Infanti L et al. Prevalence of hepatitis C virus infection in patients with lymphoproliferative disorders. Blood 1996; 87: 4296-4301.
13. de Sanjose S, Benavente Y, Vajdic CM, Engels EA, Morton LM, Bracci PM et al. Hepatitis C and non-Hodgkin lymphoma among 4784 cases and 6269 controls from the International Lymphoma Epidemiology Consortium. Clin Gastroenterol Hepatol 2008; 6: 451-458.
14. Chuang SS, Liao YL, Chang ST, Hsieh YC, Kuo SY, Lu CL et al. Hepatitis C virus infection is significantly associated with malignant lymphoma in Taiwan, particularly with nodal and splenic marginal zone lymphomas. J Clin Pathol 2010; 63: 595-598.
15. Arcaini L, Bruno R. Hepatitis C virus infection and antiviral treatment in marginal zone lymphomas. Curr Clin Pharmacol 2010; 5: 74-81.
16. Ruiz-Ballesteros E, Mollejo M, Mateo M, Algara P, Martinez P, Piris MA. MicroRNA losses in the frequently deleted region of 7q in SMZL. Leukemia 2007; 21: 2547-2549.
17. Bouteloup M, Verney A, Rachinel N, Callet-Bauchu E, Ffrench M, Coiffier B et al. MicroRNA expression profile in splenic marginal zone lymphoma. Br J Haematol 2011; 156: 279-281.
18. Jima DD, Zhang J, Jacobs C, Richards KL, Dunphy CH, Choi WW et al. Deep sequencing of the small RNA transcriptome of normal and malignant human B cells identifies hundreds of novel microRNAs. Blood 2010; 116: e118-e127.
19. Tan LP, Wang M, Robertus JL, Schakel RN, Gibcus JH, Diepstra A et al. miRNA profiling of B-cell subsets: specific miRNA profile for germinal center B cells with variation between centroblasts and centrocytes. Lab Invest 2009; 89: 708-716.
20. R Development Core Team. R: A Language and Environment for Statistical Computing. R Development Core Team: Vienna, Austria, 2005.
21. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 2004; 5: R80.
22. Bolstad BM, Irizarry RA, Astrand M, Speed TP. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 2003; 19: 185-193.
23. Dallal GE, Leland W. An analytic approximation to the distribution of lilliefors's test statistic for normality. Am Stat 1986; 40: 294-296.
24. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Statist Soc B 1995; 57: 289-300.
25. Ruiz-Ballesteros E, Mollejo M, Rodriguez A, Camacho FI, Algara P, Martinez N et al. Splenic marginal zone lymphoma: proposal of new diagnostic and prognostic markers identified after tissue and cDNA microarray analysis. Blood 2005; 106: 1831-1838.
26. Dweep H, Sticht C, Pandey P, Gretz N. miRWalk-database: prediction of possible miRNA binding sites by 'walking' the genes of three genomes. J Biomed Inform 2011; 44: 839-847.
27. John B, Enright AJ, Aravin A, Tuschl T, Sander C, Marks DS. Human MicroRNA targets. PLoS Biol 2004; 2: e363.
28. Kertesz M, Iovino N, Unnerstall U, Gaul U, Segal E. The role of site accessibility in microRNA target recognition. Nat Genet 2007; 39: 1278-1284.
29. Krek A, Grun D, Poy MN, Wolf R, Rosenberg L, Epstein EJ et al. Combinatorial microRNA target predictions. Nat Genet 2005; 37: 495-500.
30. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005; 120: 15-20.
31. Rehmsmeier M, Steffen P, Hochsmann M, Giegerich R. Fast and effective prediction of microRNA/target duplexes. RNA 2004; 10: 1507-1517.
32. Matutes E, Oscier D, Montalban C, Berger F, Callet-Bauchu E, Dogan A et al. Splenic marginal zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteria. Leukemia 2008; 22: 487-495.
33. Roehle A, Hoefig KP, Repsilber D, Thorns C, Ziepert M, Wesche KO et al. MicroRNA signatures characterize diffuse large B-cell lymphomas and follicular lymphomas. Br J Haematol 2008; 142: 732-744.
34. Cammarata G, Augugliaro L, Salemi D, Agueli C, La Rosa M, Dagnino L et al. Differential expression of specific microRNA and their targets in acute myeloid leukemia. Am J Hematol 2010; 85: 331-339.
35. Kluiver J, Poppema S, de Jong D, Blokzijl T, Harms G, Jacobs S et al. BIC and miR-155 are highly expressed in Hodgkin, primary mediastinal and diffuse large B cell lymphomas. J Pathol 2005; 207: 243-249.
36. Lawrie CH, Soneji S, Marafioti T, Cooper CD, Palazzo S, Paterson JC et al. MicroRNA expression distinguishes between germinal center B cell-like and activated B cell-like subtypes of diffuse large B cell lymphoma. Int J Cancer 2007; 121: 1156-1161.
37. Medina PP, Nolde M, Slack FJ. OncomiR addiction in an in vivo model of microRNA-21-induced pre-B-cell lymphoma. Nature 2010; 467: 86-90.
38. Thompson RC, Herscovitch M, Zhao I, Ford TJ, Gilmore TD. NF-kappaB downregulates expression of the B-lymphoma marker CD10 through a miR-155/PU.1 pathway. J Biol Chem 2011; 286: 1675-1682.
39. Jiang L, Liu X, Kolokythas A, Yu J, Wang A, Heidbreder CE et al. Downregulation of the Rho GTPase signaling pathway is involved in the microRNA-138-mediated inhibition of cell migration and invasion in tongue squamous cell carcinoma. Int J Cancer 2010; 127: 505-512.
40. Liu L, Jiang Y, Zhang H, Greenlee AR, Han Z. Overexpressed miR-494 downregulates PTEN gene expression in cells transformed by anti-benzo(a) pyrenetrans-7,8-dihydrodiol-9,10-epoxide. Life Sci 2010; 86: 192-198.
41. Rinaldi A, Mian M, Chigrinova E, Arcaini L, Bhagat G, Novak U et al. Genome-wide DNA profiling of marginal zone lymphomas identifies subtype-specific lesions with an impact on the clinical outcome. Blood 2011; 117: 1595-1604.
42. Salido M, Baro C, Oscier D, Stamatopoulos K, Dierlamm J, Matutes E et al. Cytogenetic aberrations and their prognostic value in a series of 330 splenic marginal zone B-cell lymphomas: a multicenter study of the Splenic B-Cell Lymphoma Group. Blood 2010; 116: 1479-1488.
43. Rossi D, Deaglio S, Dominguez-Sola D, Rasi S, Vaisitti T, Agostinelli C et al. Alteration of BIRC3 and multiple other NF-kappaB pathway genes in splenic marginal zone lymphoma. Blood 2011; 118: 4930-4934.
44. Ma X, Becker Buscaglia LE, Barker JR, Li Y. MicroRNAs in NF-kappaB signaling. J Mol Cell Biol 2011; 3: 159-166.
45. Marquez RT, Bandyopadhyay S, Wendlandt EB, Keck K, Hoffer BA, Icardi MS et al. Correlation between microRNA expression levels and clinical parameters associated with chronic hepatitis C viral infection in humans. Lab Invest 2010; 90: 1727-1736.
46. Bihrer V, Waidmann O, Friedrich-Rust M, Forestier N, Susser S, Haupenthal J et al. Serum microRNA-21 as marker for necroinflammation in hepatitis C patients with and without hepatocellular carcinoma. PLoS One 2011; 6: e26971.
47. Cermelli S, Ruggieri A, Marrero JA, Ioannou GN, Beretta L. Circulating microRNAs in patients with chronic hepatitis C and non-alcoholic fatty liver disease. PLoS One 2011; 6: e23937.
48. Murakami Y, Yasuda T, Saigo K, Urashima T, Toyoda H, Okanoue T et al. Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues. Oncogene 2006; 25: 2537-2545.
49. Ura S, Honda M, Yamashita T, Ueda T, Takatori H, Nishino R et al. Differential microRNA expression between hepatitis B and hepatitis C leading disease progression to hepatocellular carcinoma. Hepatology 2009; 49: 1098-1112.
50. Ji J, Shi J, Budhu A, Yu Z, Forgues M, Roessler S et al. MicroRNA expression, survival, and response to interferon in liver cancer. N Engl J Med 2009; 361: 1437-1447.
51. Gao W, Shen H, Liu L, Xu J, Shu Y. MiR-21 overexpression in human primary squamous cell lung carcinoma is associated with poor patient prognosis. J Cancer Res Clin Oncol 2010; 137: 557-566.
52. Malumbres R, Sarosiek KA, Cubedo E, Ruiz JW, Jiang X, Gascoyne RD et al. Differentiation stage-specific expression of microRNAs in B lymphocytes and diffuse large B-cell lymphomas. Blood 2009; 113: 3754-3764.
53. Ma YL, Zhang P, Wang F, Moyer MP, Yang JJ, Liu ZH et al. Human embryonic stem cells and metastatic colorectal cancer cells shared the common endogenous human microRNA-26b. J Cell Mol Med 2010; 15: 1941-1954.
54. Gisbert JP, Garcia-Buey L, Pajares JM, Moreno-Otero R. Prevalence of hepatitis C virus infection in B-cell non-Hodgkin's lymphoma: systematic review and metaanalysis. Gastroenterology 2003; 125: 1723-1732.
55. Negri E, Little D, Boiocchi M, La Vecchia C, Franceschi S. B-cell non-Hodgkin's lymphoma and hepatitis C virus infection: a systematic review. Int J Cancer 2004; 111: 1-8.
56. Chen J, Li L, Zhang Y, Yang H, Wei Y, Zhang L et al. Interaction of Pin1 with Nek6 and characterization of their expression correlation in Chinese hepatocellular carcinoma patients. Biochem Biophys Res Commun 2006; 341: 1059-1065.
57. Nassirpour R, Shao L, Flanagan P, Abrams T, Jallal B, Smeal T et al. Nek6 mediates human cancer cell transformation and is a potential cancer therapeutic target. Mol Cancer Res 2010; 8: 717-728.
58. Takeno A, Takemasa I, Doki Y, Yamasaki M, Miyata H, Takiguchi S et al. Integrative approach for differentially overexpressed genes in gastric cancer by combining largescale gene expression profiling and network analysis. Br J Cancer 2008; 99: 1307-1315.
59. Jee HJ, Kim AJ, Song N, Kim HJ, Kim M, Koh H et al. Nek6 overexpression antagonizes p53-induced senescence in human cancer cells. Cell Cycle 2010; 9: 4703-4710.